1Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver muta- tions in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol, 2011, 29(suppl): abstract CRATS06.
2Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One, 2011, 6(11): e28204.
3Mollberg N, Surati M, Demchuk C, et al. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther, 2011, 28(3): 173-194.
4Dacic S. Molecular diagnostics of lung carcinomas. Arch Pathol Lab Med, 2011, 135(5): 622-629.
5Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treat- ed non-small-cell lung cancer (INTEREST): a randomised phase Ⅲ trial. Lancet, 2008, 372(9652): 1809-1818.
6Mok TS, Wu YL, "Ihongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N EnglJ Med, 2009, 361 (10): 947-957.
7Zhou C, Wu YL, Chen G, et al. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).J Clin Oncol, 2011, 29(suppl ): abstract 7520.
8Wu YL, I(im JH, Park K, et al. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase Ⅲ, randomized SATURN study. Lung Cancer, 2012, 77(2): 339-345.
9Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase Ⅲ randomized trial.J Clin Oncol, 2011, 29(suppl): abstract 7503.
10Ayoola A, Barochia A, Belani K, et al. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest, 2012, 30(5): 433-446.
